MA32481B1 - Compositions et procédés d'utilisation pour des anticorps thérapeutiques - Google Patents

Compositions et procédés d'utilisation pour des anticorps thérapeutiques

Info

Publication number
MA32481B1
MA32481B1 MA33525A MA33525A MA32481B1 MA 32481 B1 MA32481 B1 MA 32481B1 MA 33525 A MA33525 A MA 33525A MA 33525 A MA33525 A MA 33525A MA 32481 B1 MA32481 B1 MA 32481B1
Authority
MA
Morocco
Prior art keywords
compositions
methods
antibodies
therapeutic antibodies
baffr
Prior art date
Application number
MA33525A
Other languages
Arabic (ar)
English (en)
Inventor
Christoph Heusser
Julia Neugebauer
Eveline Schaadt
Stefanie Urlinger
Maximilian Woisetschlaeger
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41073830&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32481(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA32481B1 publication Critical patent/MA32481B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention porte sur des anticorps qui se lient de façon spécifique au récepteur baff (baffr). Plus spécifiquement, l'invention porte sur des anticorps qui sont des antagonistes de baffr avec une activité de déplétion des cellules b in vivo, et sur des compositions et procédés d'utilisation pour lesdits anticorps pour traiter des troubles pathologiques qui peuvent être traités par destruction ou déplétion des cellules b, tels que le lupus érythémateux systémique ou la polyarthrite rhumatoïde ou d'autres maladies auto-immunes, des lymphomes, des leucémies ou des myélomes.
MA33525A 2008-07-17 2011-01-14 Compositions et procédés d'utilisation pour des anticorps thérapeutiques MA32481B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08160671 2008-07-17
EP09160326 2009-05-15
PCT/EP2009/059030 WO2010007082A1 (fr) 2008-07-17 2009-07-15 Compositions et procédés d'utilisation pour des anticorps thérapeutiques

Publications (1)

Publication Number Publication Date
MA32481B1 true MA32481B1 (fr) 2011-07-03

Family

ID=41073830

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33525A MA32481B1 (fr) 2008-07-17 2011-01-14 Compositions et procédés d'utilisation pour des anticorps thérapeutiques

Country Status (40)

Country Link
US (3) US8106163B2 (fr)
EP (1) EP2315780B8 (fr)
JP (2) JP5767109B2 (fr)
KR (2) KR101314369B1 (fr)
CN (1) CN102119174B (fr)
AR (1) AR072749A1 (fr)
AU (1) AU2009272771B2 (fr)
BR (1) BRPI0915928B8 (fr)
CA (1) CA2730063C (fr)
CL (1) CL2011000086A1 (fr)
CR (1) CR11863A (fr)
CU (1) CU23878B1 (fr)
CY (1) CY1116800T1 (fr)
DK (1) DK2315780T3 (fr)
DO (1) DOP2011000016A (fr)
EA (1) EA024492B1 (fr)
EC (1) ECSP11010761A (fr)
ES (1) ES2547270T3 (fr)
GE (1) GEP20146129B (fr)
HR (1) HRP20151227T1 (fr)
HU (1) HUE025778T2 (fr)
IL (1) IL210485A (fr)
JO (1) JO3149B1 (fr)
MA (1) MA32481B1 (fr)
MX (1) MX2011000616A (fr)
MY (1) MY158980A (fr)
NI (1) NI201100017A (fr)
NZ (1) NZ590057A (fr)
PE (1) PE20110563A1 (fr)
PL (1) PL2315780T3 (fr)
PT (1) PT2315780E (fr)
RS (1) RS54299B1 (fr)
SG (1) SG193805A1 (fr)
SI (1) SI2315780T1 (fr)
SM (1) SMP201100010B (fr)
SV (1) SV2011003807A (fr)
TW (1) TWI508742B (fr)
UY (1) UY31987A (fr)
WO (1) WO2010007082A1 (fr)
ZA (1) ZA201008952B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2222846B1 (fr) * 2007-08-10 2017-05-03 Protelix, Inc. Bibliothèques universelles de domaines de liaison de la fibronectine de type iii
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
US8680019B2 (en) * 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
US9458240B2 (en) * 2010-12-10 2016-10-04 Novartis Pharma Ag Anti-BAFFR antibody formulations
JP2012153788A (ja) * 2011-01-25 2012-08-16 Nitto Denko Corp 光学用粘着シート
HUE028603T2 (en) * 2011-05-13 2016-12-28 Ganymed Pharmaceuticals Ag Antibodies for treatment of cancer expressing claudin 6
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
US10435474B2 (en) 2013-12-24 2019-10-08 Ossianix, Inc. Baff selective binding compounds and related methods
EA033604B1 (ru) 2014-01-31 2019-11-08 Boehringer Ingelheim Int Молекула анти-baff антитела, фармацевтическая композиция, содержащая эту молекулу, способы ее применения и кодирующий ее изолированный полинуклеотид
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
UY36351A (es) 2014-10-14 2016-06-01 Novartis Ag Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
CN108025051B (zh) 2015-07-29 2021-12-24 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
EP3316902A1 (fr) 2015-07-29 2018-05-09 Novartis AG Polythérapies comprenant des molécules d'anticorps contre tim -3
LT3317301T (lt) 2015-07-29 2021-07-26 Novartis Ag Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3
ES2986067T3 (es) 2015-12-17 2024-11-08 Novartis Ag Moléculas de anticuerpos frente a PD-1 y usos de las mismas
JP7132123B2 (ja) 2016-02-10 2022-09-06 ノバルティス アーゲー 原発性シェーグレン症候群の治療のためのｐｉ３ｋの活性阻害剤または機能阻害剤の使用
EP3464374B1 (fr) * 2016-06-06 2025-08-06 City of Hope Anticorps baff-r et utilisations de ceux-ci
BR112019012354A2 (pt) 2016-12-21 2019-11-26 Teneobio, Inc. anticorpos apenas de cadeia pesada anti-bcma
US11197928B2 (en) 2017-01-13 2021-12-14 Board Of Regents, The University Of Texas System Sustained production of high affinity antigen specific antibody by high dose BAFF receptor-targeting mAb-siRNA conjugate
MA50435A (fr) * 2017-05-24 2020-09-02 Als Therapy Development Inst Anticorps anti-ligand anti-cd40 thérapeutiques
CN110891971B (zh) * 2017-06-20 2024-01-12 特尼奥生物股份有限公司 仅有重链的抗bcma抗体
SG11202011597RA (en) * 2018-07-20 2020-12-30 Teneobio Inc Heavy chain antibodies binding to cd19
MX2021011464A (es) * 2019-03-29 2021-10-22 Chugai Pharmaceutical Co Ltd Inhibidor que contiene anticuerpo del receptor anti-interleucina 6 (il-6) para inhibir el deterioro de la funcion de la barrera hemato-encefalica (bbb).
TWI905099B (zh) 2019-05-21 2025-11-21 瑞士商諾華公司 Cd19 結合分子及其用途
EP4055047A1 (fr) * 2019-11-06 2022-09-14 Novartis AG Traitement du syndrome de sjögren
CN112813099A (zh) * 2019-11-15 2021-05-18 上海细胞治疗集团有限公司 一种在活化的t细胞中具有高活性的启动子
CN116096414A (zh) * 2020-08-04 2023-05-09 诺华股份有限公司 Cll的治疗
WO2022031567A1 (fr) 2020-08-04 2022-02-10 Novartis Ag Traitement de malignités des lymphocytes b
CN118459585A (zh) * 2020-09-07 2024-08-09 白先宏 Baff-r结合分子及其应用
WO2022097061A1 (fr) 2020-11-06 2022-05-12 Novartis Ag Polythérapie à base d'agents anti-cd19 et d'agents de ciblage de lymphocytes b pour traiter des malignités à lymphocytes b
CN115073598B (zh) * 2021-03-15 2024-02-20 盛禾(中国)生物制药有限公司 一种抗baffr抗体及其应用
EP4334351A1 (fr) 2021-05-04 2024-03-13 Novartis AG Traitement du lupus érythémateux disséminé à l'aide d'anticorps anti-baffr
CN117203240A (zh) 2021-05-04 2023-12-08 诺华股份有限公司 使用抗baffr抗体治疗狼疮肾炎
CA3233246A1 (fr) * 2021-09-29 2023-04-06 Dragonfly Therapeutics, Inc. Anticorps ciblant baff-r et leur utilisation
TW202440636A (zh) 2023-03-21 2024-10-16 美商傳記５５有限公司 Ｃｄ１９／ｃｄ３８多特異性抗體
WO2025058962A1 (fr) * 2023-09-11 2025-03-20 Absci Corporation Procédés à haut rendement pour caractérisation cinétique, quantification et optimisation d'anticorps et d'expression de fragments d'anticorps dans des bactéries
WO2025131888A1 (fr) 2023-12-19 2025-06-26 Basf Se Polyalkylène imines alcoxylées modifiées ou polyamines alcoxylées modifiées
WO2025221674A1 (fr) * 2024-04-15 2025-10-23 Eli Lilly And Company Anticorps bispécifiques baffr x cd3 et procédés d'utilisation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090016772A (ko) * 1999-08-17 2009-02-17 바이오겐 아이덱 엠에이 인코포레이티드 Ｂａｆｆ 수용체(ｂｃｍａ), 면역조절제
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
CN101120021A (zh) * 2004-12-31 2008-02-06 基因技术公司 结合br3的多肽及其用途
US20100166741A1 (en) * 2006-07-13 2010-07-01 Genentech , Inc. Altered br-3 binding polypeptides

Also Published As

Publication number Publication date
IL210485A (en) 2015-03-31
BRPI0915928B1 (pt) 2020-10-20
JP5767109B2 (ja) 2015-08-19
US8106163B2 (en) 2012-01-31
ZA201008952B (en) 2012-01-25
KR101314369B1 (ko) 2013-10-10
RS54299B1 (sr) 2016-02-29
JP2015133983A (ja) 2015-07-27
CY1116800T1 (el) 2017-03-15
PE20110563A1 (es) 2011-08-29
CU23878B1 (es) 2013-04-19
HK1150839A1 (en) 2012-01-13
CA2730063A1 (fr) 2010-01-21
NI201100017A (es) 2012-08-17
TW201006493A (en) 2010-02-16
BRPI0915928A2 (pt) 2015-11-03
SI2315780T1 (sl) 2015-11-30
BRPI0915928B8 (pt) 2021-05-25
SMP201100010B (it) 2011-09-09
ECSP11010761A (es) 2011-02-28
WO2010007082A1 (fr) 2010-01-21
KR20110020914A (ko) 2011-03-03
CA2730063C (fr) 2017-04-18
CL2011000086A1 (es) 2011-07-01
TWI508742B (zh) 2015-11-21
PL2315780T3 (pl) 2016-01-29
CU20110013A7 (es) 2012-06-21
JO3149B1 (ar) 2017-09-20
EP2315780B1 (fr) 2015-08-19
JP2011527896A (ja) 2011-11-10
IL210485A0 (en) 2011-03-31
EA201100191A1 (ru) 2011-08-30
US9382326B2 (en) 2016-07-05
SV2011003807A (es) 2011-03-23
JP6077587B2 (ja) 2017-02-08
US20120195913A1 (en) 2012-08-02
MX2011000616A (es) 2011-02-24
AU2009272771A1 (en) 2010-01-21
SG193805A1 (en) 2013-10-30
KR101545795B1 (ko) 2015-08-19
CR11863A (es) 2011-02-11
ES2547270T3 (es) 2015-10-05
UY31987A (es) 2010-02-26
GEP20146129B (en) 2014-08-11
NZ590057A (en) 2012-08-31
PT2315780E (pt) 2015-11-30
CN102119174B (zh) 2015-01-21
EA024492B1 (ru) 2016-09-30
EP2315780A1 (fr) 2011-05-04
HRP20151227T1 (hr) 2015-12-18
AU2009272771B2 (en) 2012-09-20
HUE025778T2 (en) 2016-05-30
US9340620B2 (en) 2016-05-17
DOP2011000016A (es) 2011-02-15
US20100021452A1 (en) 2010-01-28
MY158980A (en) 2016-11-30
CN102119174A (zh) 2011-07-06
EP2315780B8 (fr) 2015-09-23
SMAP201100010A (it) 2011-05-06
US20120183529A1 (en) 2012-07-19
DK2315780T3 (en) 2015-10-19
KR20130098432A (ko) 2013-09-04
AR072749A1 (es) 2010-09-15

Similar Documents

Publication Publication Date Title
MA32481B1 (fr) Compositions et procédés d'utilisation pour des anticorps thérapeutiques
EP2322557A3 (fr) Compositions et procédés pour traiter des maladies prolifératives
EA201100524A1 (ru) Азаиндазолы в качестве антагонистов рецептора ccr1
MA32190B1 (fr) Anticorps dirigés contre l'angiopoïétine 1 et l'angiopoïétine 2 et leur utilisation
MX2011011338A (es) Composiciones y metodos de uso para anticuerpos terapeuticos especificos para la subunidad beta1 del receptor de il-12.
TN2019000099A1 (fr) Anticorps anti-lag-3 et compositions
EA201500393A1 (ru) Ингибиторы тирозинкиназы брутона
MA35661B1 (fr) Inhibiteurs de pak pour le traitement de troubles de prolifération cellulaire
MY160590A (en) Cd127 binding proteins
MY177970A (en) Bcma (cd269/tnfrsf17) -binding proteins
EA202092589A2 (ru) Cxcr2-связывающие полипептиды
MX356107B (es) Histidil-arnt sintetasas para tratar enfermedades autoinmunes e inflamatorias.
TW200730624A (en) Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
WO2012118750A3 (fr) Marqueurs biologiques et procédés de prédiction de réponse à des antagonistes de lymphocytes b
MA33208B1 (fr) Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
EA201100452A1 (ru) Лечение воспалительных состояний
HK1210792A1 (en) Molecules with antigen binding and polyvalent fc gamma receptor binding activity
MX2014008646A (es) Composiciones utiles como arenas sanitarias para animales.
WO2006125640A3 (fr) Production et profilage d'anticorps therapeutiques entierement humains hucal gold®; propres a la molecule cd38 humaine
PL1830881T3 (pl) Terapie skojarzone celowane na wiele receptorów Toll-podobnych i ich zastosowanie
MY145810A (en) Il-8 receptor antagonists
SG178976A1 (en) High affinity human antibodies to human protease-activated receptor-2
WO2011098762A8 (fr) Anticorps
GB2453068A (en) Novel hepatocyte-like cells and hepatoblast-like cells derived from hbs cells
JO3579B1 (ar) مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول